The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration

Jared T. Hinkle, Valina Dawson, Ted M Dawson

Research output: Contribution to journalArticle

Abstract

We recently demonstrated that NLY01, a novel glucagon-like peptide-1 receptor agonist, exerts neuroprotective effects in two mouse models of PD in a glia-dependent manner. NLY01 prevented microglia from releasing inflammatory mediators known to convert astrocytes into a neurotoxic A1 reactive subtype. Importantly, we provided evidence that this neuroprotection was not mediated by a direct action of NLY01 on neurons or astrocytes (e.g., by activating neurotrophic pathways or modulating astrocyte reactivity per se). In the present article, we provide a generalist review of microglia and astrocytes in neurodegeneration and discuss the emerging paradigm of A1 astrocyte neurotoxicity in more detail. We comment on specific inferences that are naturally suggested by our work in this area and the differential level of support it offers to each. Finally, we discuss implications for the overall goal of creating disease-modifying therapies for PD, survey emerging methodologies for accelerating translational research on glia in neurodegeneration, and describe expected challenges for developing glia-directed therapies that do not impede essential physiological functions carried out by glia in the CNS.

Original languageEnglish (US)
Pages (from-to)959-969
Number of pages11
JournalMovement Disorders
Volume34
Issue number7
DOIs
StatePublished - Jul 1 2019

Fingerprint

Astrocytes
Neuroglia
Pharmacology
Microglia
Translational Medical Research
Neuroprotective Agents
Neurons
Therapeutics

Keywords

  • astrocytes
  • microglia
  • neurodegeneration
  • NLY01
  • Parkinson's disease

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

The A1 astrocyte paradigm : New avenues for pharmacological intervention in neurodegeneration. / Hinkle, Jared T.; Dawson, Valina; Dawson, Ted M.

In: Movement Disorders, Vol. 34, No. 7, 01.07.2019, p. 959-969.

Research output: Contribution to journalArticle

@article{d5eea118b29f49899cd07b6e94e2fd98,
title = "The A1 astrocyte paradigm: New avenues for pharmacological intervention in neurodegeneration",
abstract = "We recently demonstrated that NLY01, a novel glucagon-like peptide-1 receptor agonist, exerts neuroprotective effects in two mouse models of PD in a glia-dependent manner. NLY01 prevented microglia from releasing inflammatory mediators known to convert astrocytes into a neurotoxic A1 reactive subtype. Importantly, we provided evidence that this neuroprotection was not mediated by a direct action of NLY01 on neurons or astrocytes (e.g., by activating neurotrophic pathways or modulating astrocyte reactivity per se). In the present article, we provide a generalist review of microglia and astrocytes in neurodegeneration and discuss the emerging paradigm of A1 astrocyte neurotoxicity in more detail. We comment on specific inferences that are naturally suggested by our work in this area and the differential level of support it offers to each. Finally, we discuss implications for the overall goal of creating disease-modifying therapies for PD, survey emerging methodologies for accelerating translational research on glia in neurodegeneration, and describe expected challenges for developing glia-directed therapies that do not impede essential physiological functions carried out by glia in the CNS.",
keywords = "astrocytes, microglia, neurodegeneration, NLY01, Parkinson's disease",
author = "Hinkle, {Jared T.} and Valina Dawson and Dawson, {Ted M}",
year = "2019",
month = "7",
day = "1",
doi = "10.1002/mds.27718",
language = "English (US)",
volume = "34",
pages = "959--969",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "7",

}

TY - JOUR

T1 - The A1 astrocyte paradigm

T2 - New avenues for pharmacological intervention in neurodegeneration

AU - Hinkle, Jared T.

AU - Dawson, Valina

AU - Dawson, Ted M

PY - 2019/7/1

Y1 - 2019/7/1

N2 - We recently demonstrated that NLY01, a novel glucagon-like peptide-1 receptor agonist, exerts neuroprotective effects in two mouse models of PD in a glia-dependent manner. NLY01 prevented microglia from releasing inflammatory mediators known to convert astrocytes into a neurotoxic A1 reactive subtype. Importantly, we provided evidence that this neuroprotection was not mediated by a direct action of NLY01 on neurons or astrocytes (e.g., by activating neurotrophic pathways or modulating astrocyte reactivity per se). In the present article, we provide a generalist review of microglia and astrocytes in neurodegeneration and discuss the emerging paradigm of A1 astrocyte neurotoxicity in more detail. We comment on specific inferences that are naturally suggested by our work in this area and the differential level of support it offers to each. Finally, we discuss implications for the overall goal of creating disease-modifying therapies for PD, survey emerging methodologies for accelerating translational research on glia in neurodegeneration, and describe expected challenges for developing glia-directed therapies that do not impede essential physiological functions carried out by glia in the CNS.

AB - We recently demonstrated that NLY01, a novel glucagon-like peptide-1 receptor agonist, exerts neuroprotective effects in two mouse models of PD in a glia-dependent manner. NLY01 prevented microglia from releasing inflammatory mediators known to convert astrocytes into a neurotoxic A1 reactive subtype. Importantly, we provided evidence that this neuroprotection was not mediated by a direct action of NLY01 on neurons or astrocytes (e.g., by activating neurotrophic pathways or modulating astrocyte reactivity per se). In the present article, we provide a generalist review of microglia and astrocytes in neurodegeneration and discuss the emerging paradigm of A1 astrocyte neurotoxicity in more detail. We comment on specific inferences that are naturally suggested by our work in this area and the differential level of support it offers to each. Finally, we discuss implications for the overall goal of creating disease-modifying therapies for PD, survey emerging methodologies for accelerating translational research on glia in neurodegeneration, and describe expected challenges for developing glia-directed therapies that do not impede essential physiological functions carried out by glia in the CNS.

KW - astrocytes

KW - microglia

KW - neurodegeneration

KW - NLY01

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=85069505088&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069505088&partnerID=8YFLogxK

U2 - 10.1002/mds.27718

DO - 10.1002/mds.27718

M3 - Article

C2 - 31136698

AN - SCOPUS:85069505088

VL - 34

SP - 959

EP - 969

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 7

ER -